Equillium opened lower at $1.40, compared with its previous close of $1.42. In the last trading session, the stock traded between $1.34 and $1.40. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Equillium is now worth
$ 23.12
Resulting in a loss of
$ 76.88 (76.88%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.11 (-7.68%)
Day High
$1.40
Day Low
$1.34
Day Open
$1.40
Prev Close
$1.42
Volume
1,47,168
1W Return
-5.82%
1M Return
-12.89%
3M Return
-41.50%
6M Return
-41.73%
1Y Return
35.02%
Fundamentals
Market Cap ($ Mn)
83
PE Ratio
-
PB Ratio
2.71
PEG Ratio
-
ROE
-118.85%
ROCE
-121.62%
EPS (TTM)
$-0.07
Investment Returns
1 Week
-5.82%
1 Month
-12.89%
3 Months
-41.50%
6 Months
-41.73%
9 Months
-15.42%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
13Nov
Equillium Q3 Results: Loss narrows to $0.04 per share, beats estimate
Equillium Inc reported a loss of $0.04 per share for Q3. The result beat the analyst consensus estimate of $0.05 by 20%. Quarterly losses improved by 33.33% compared to the same period last year.
Today
6Oct
Equillium secures Australian clearance for first-in-human EQ504 trial
Received HREC approval and TGA clearance in Australia for Phase 1 trial. Dosing of healthy participants expected to begin by early November 2026. Topline Phase 1 proof-of-mechanism data anticipated six months after initiation. Trial evaluates safety, tolerability, PK, and PD of oral doses from 0.1-3.0 mg. Plans to initiate Phase 2 proof-of-concept study in second half of 2027.
1mo ago
16Sep
Equillium management to speak at Stifel immunology forum
Equillium management to hold fireside chat at Stifel forum. Event scheduled for September 23, 2026, at 12:00 pm EDT. Live webcast accessible via company investor relations page. Replay available for approximately 45 days post-event.
1mo ago
13Jul
Piper Sandler initiates coverage on Equillium with Overweight rating
Piper Sandler analyst Yasmeen Rahimi has initiated coverage on Equillium with an Overweight rating and a price target of $20. The rating indicates a positive outlook for the stock.
